Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for refractory overuse rotator cuff tendinopathy
NL-OMON44187Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in shoulder tendinopathy comparing Secukinumab with Placebo (2 arms). Primary endpoint: Western Ontario Rotator Cuff score at week 14. Started Oct 2017; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
shoulder tendinopathy
Beyond the preview
Go deeper on NL-OMON44187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44187.